TrialGynecologic oncology2011

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Kian Behbakht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.